Literature DB >> 26676749

Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer.

Fernando Concha-Benavente1, Raghvendra M Srivastava2, Sumita Trivedi2, Yu Lei3, Uma Chandran4, Raja R Seethala5, Gordon J Freeman6, Robert L Ferris7.   

Abstract

Many cancer types, including head and neck cancers (HNC), express programmed death ligand 1 (PD-L1). Interaction between PD-L1 and its receptor, programmed death 1 (PD-1), inhibits the function of activated T cells and results in an immunosuppressive microenvironment, but the stimuli that induce PD-L1 expression are not well characterized. Interferon gamma (IFNγ) and the epidermal growth factor receptor (EGFR) utilize Janus kinase 2 (JAK2) as a common signaling node to transmit tumor cell-mediated extrinsic or intrinsic signals, respectively. In this study, we investigated the mechanism by which these factors upregulate PD-L1 expression in HNC cells in the context of JAK/STAT pathway activation, Th1 inflammation, and HPV status. We found that wild-type, overexpressed EGFR significantly correlated with JAK2 and PD-L1 expression in a large cohort of HNC specimens. Furthermore, PD-L1 expression was induced in an EGFR- and JAK2/STAT1-dependent manner, and specific JAK2 inhibition prevented PD-L1 upregulation in tumor cells and enhanced their immunogenicity. Collectively, our findings suggest a novel role for JAK2/STAT1 in EGFR-mediated immune evasion, and therapies targeting this signaling axis may be beneficial to block PD-L1 upregulation found in a large subset of HNC tumors. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26676749      PMCID: PMC4775348          DOI: 10.1158/0008-5472.CAN-15-2001

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck.

Authors:  Kazuaki Chikamatsu; Koichi Sakakura; Minoru Toyoda; Katsumasa Takahashi; Takanori Yamamoto; Keisuke Masuyama
Journal:  Cancer Sci       Date:  2012-04-11       Impact factor: 6.716

2.  STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC Cells.

Authors:  Nicole C Schmitt; Sumita Trivedi; Robert L Ferris
Journal:  Mol Cancer Ther       Date:  2015-07-03       Impact factor: 6.261

3.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Authors:  Esra A Akbay; Shohei Koyama; Julian Carretero; Abigail Altabef; Jeremy H Tchaicha; Camilla L Christensen; Oliver R Mikse; Andrew D Cherniack; Ellen M Beauchamp; Trevor J Pugh; Matthew D Wilkerson; Peter E Fecci; Mohit Butaney; Jacob B Reibel; Margaret Soucheray; Travis J Cohoon; Pasi A Janne; Matthew Meyerson; D Neil Hayes; Geoffrey I Shapiro; Takeshi Shimamura; Lynette M Sholl; Scott J Rodig; Gordon J Freeman; Peter S Hammerman; Glenn Dranoff; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2013-09-27       Impact factor: 39.397

Review 4.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Curr Opin Immunol       Date:  2012-01-09       Impact factor: 7.486

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  Recruitment of Stat1 to chromatin is required for interferon-induced serine phosphorylation of Stat1 transactivation domain.

Authors:  Iwona Sadzak; Melanie Schiff; Irene Gattermeier; Reingard Glinitzer; Ines Sauer; Armin Saalmüller; Edward Yang; Barbara Schaljo; Pavel Kovarik
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-23       Impact factor: 11.205

7.  SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells.

Authors:  Michael S Leibowitz; Raghvendra M Srivastava; Pedro A Andrade Filho; Ann Marie Egloff; Lin Wang; Raja R Seethala; Soldano Ferrone; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2013-01-30       Impact factor: 12.531

8.  B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma.

Authors:  Odey C Ukpo; Wade L Thorstad; James S Lewis
Journal:  Head Neck Pathol       Date:  2012-11-20

9.  PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.

Authors:  Cécile Badoual; Stéphane Hans; Nathalie Merillon; Cordélia Van Ryswick; Patrice Ravel; Nadine Benhamouda; Emeline Levionnois; Mevyn Nizard; Ali Si-Mohamed; Nicolas Besnier; Alain Gey; Rinat Rotem-Yehudar; Hélène Pere; Thi Tran; Coralie L Guerin; Anne Chauvat; Estelle Dransart; Cécile Alanio; Sebastien Albert; Beatrix Barry; Federico Sandoval; Françoise Quintin-Colonna; Patrick Bruneval; Wolf H Fridman; Francois M Lemoine; Stephane Oudard; Ludger Johannes; Daniel Olive; Daniel Brasnu; Eric Tartour
Journal:  Cancer Res       Date:  2012-11-07       Impact factor: 12.701

10.  Chromatin immunoprecipitation: optimization, quantitative analysis and data normalization.

Authors:  Max Haring; Sascha Offermann; Tanja Danker; Ina Horst; Christoph Peterhansel; Maike Stam
Journal:  Plant Methods       Date:  2007-09-24       Impact factor: 4.993

View more
  108 in total

Review 1.  Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.

Authors:  Joshua D Horton; Hannah M Knochelmann; Terry A Day; Chrystal M Paulos; David M Neskey
Journal:  Trends Cancer       Date:  2019-03-20

2.  BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.

Authors:  J Wang; Y Jia; S Zhao; X Zhang; X Wang; X Han; Y Wang; M Ma; J Shi; L Liu
Journal:  Oncogene       Date:  2017-07-17       Impact factor: 9.867

3.  STAT1 inhibits T-cell exhaustion and myeloid derived suppressor cell accumulation to promote antitumor immune responses in head and neck squamous cell carcinoma.

Authors:  Nathan Ryan; Kelvin Anderson; Greta Volpedo; Omar Hamza; Sanjay Varikuti; Abhay R Satoskar; Steve Oghumu
Journal:  Int J Cancer       Date:  2019-11-29       Impact factor: 7.396

Review 4.  Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.

Authors:  Jessica M Moskovitz; Jennifer Moy; Tanguy Y Seiwert; Robert L Ferris
Journal:  Oncologist       Date:  2017-05-15

5.  GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC.

Authors:  Chengzhong Lin; Wei Cao; Zhenhu Ren; Yu Tang; Chunye Zhang; Rong Yang; Yiming Chen; Zheqi Liu; Canbang Peng; Lizhen Wang; Xu Wang; Tong Ji
Journal:  Oncoimmunology       Date:  2017-07-20       Impact factor: 8.110

6.  HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers.

Authors:  Sara I Pai; J Jack Lee; Thomas E Carey; William H Westra; Soldano Ferrone; Charles Moore; Marina B Mosunjac; Dong M Shin; Robert L Ferris
Journal:  Oral Oncol       Date:  2017-12-28       Impact factor: 5.337

7.  Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma.

Authors:  Ayman Oweida; Shelby Lennon; Dylan Calame; Sean Korpela; Shilpa Bhatia; Jaspreet Sharma; Caleb Graham; David Binder; Natalie Serkova; David Raben; Lynn Heasley; Eric Clambey; Raphael Nemenoff; Sana D Karam
Journal:  Oncoimmunology       Date:  2017-08-03       Impact factor: 8.110

Review 8.  Checkpoint immunotherapy in head and neck cancers.

Authors:  Paul Zolkind; Ravindra Uppaluri
Journal:  Cancer Metastasis Rev       Date:  2017-09       Impact factor: 9.264

9.  PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients.

Authors:  Fernando Concha-Benavente; Benjamin Kansy; Jessica Moskovitz; Jennifer Moy; Uma Chandran; Robert L Ferris
Journal:  Cancer Immunol Res       Date:  2018-10-03       Impact factor: 11.151

10.  PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer.

Authors:  Benjamin A Kansy; Fernando Concha-Benavente; Raghvendra M Srivastava; Hyun-Bae Jie; Gulidanna Shayan; Yu Lei; Jessica Moskovitz; Jennifer Moy; Jing Li; Sven Brandau; Stephan Lang; Nicole C Schmitt; Gordon J Freeman; William E Gooding; David A Clump; Robert L Ferris
Journal:  Cancer Res       Date:  2017-09-13       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.